Related Experiment Video
Updated: Apr 13, 2026

Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring
Published on: December 9, 2010
An Australian perspective on clinical, economic and regulatory considerations in emerging nanoparticle therapies for
Benjamin W Muir1, Jennifer A E Payne2, Jennifer H Martin3
1Commonwealth Scientific and Industrial Research Organisation, Clayton, VIC, Australia. ben.muir@csiro.au.
Abstract:
Antimicrobial resistance (AMR) poses a growing global health threat. Nanomedicine, combined with drug repurposing, may help extend the effective lifespan of current and new antimicrobials. This review, presents an Australian perspective on nanotechnology-based therapies, highlighting scientific and clinical challenges. Early consideration of the potential barriers to market access may help to accelerate research translation, regulatory approval and patient access to nano-antimicrobial (NAM) drugs for resistant pathogens, not only in Australia, but globally.
Related Concept Videos
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Microorganisms in Medicine and Therapeutics
Microbial Corrosion
Inhibitors of Viral Protein Synthesis
Clinical Significance of Antibiotic Resistance

